Copyright
©The Author(s) 2022.
World J Psychiatry. Sep 19, 2022; 12(9): 1183-1193
Published online Sep 19, 2022. doi: 10.5498/wjp.v12.i9.1183
Published online Sep 19, 2022. doi: 10.5498/wjp.v12.i9.1183
Table 1 Demographic and clinical characteristics of subjects
| Characteristics | SC in remission (n = 27) | Healthy control (n = 18) | P value |
| Age (yr), mean ± SD | 36.18 ± 9.27 | 37.67 ± 9.96 | 0.862 |
| Sex (male/female) | 16/11 | 12/6 | 0.851 |
| Duration of illness (yr), mean ± SD | 9.95 ± 7.71 | - | - |
| Number of previous hospitalizations | 2.18 ± 1.92 | - | - |
| PANSS | |||
| PANSS total score | 99.22 ± 18.2 | - | - |
| Positive syndrome scale | 22.26 ± 5.97 | - | - |
| Negative syndrome scale | 27.52 ± 6.09 | - | - |
| General psychopathology scale | 49.44 ± 7.83 | - | - |
| MoCA | |||
| MoCA total score | 22.74 ± 4.76 | - | - |
| Visuospatial/Executive | 4.11 ± 1.25 | - | - |
| Naming | 2.78 ± 0.69 | - | - |
| Attention | 5.07 ± 1.21 | - | - |
| Language | 1.89 ± 0.69 | - | - |
| Abstraction | 1.41 ± 0.84 | - | - |
| Delayed recall | 1.81 ± 1.62 | - | - |
| Orientation | 5.74 ± 0.81 | - | - |
| Medications | |||
| Long-acting risperidone/paliperidone | 22/5 | - | - |
| Long-acting risperidone dosage 25/37.5/50 mg | 3/9/13 | - | - |
| Cell counts | |||
| Leukocytes (× 109/L) | 6.67 ± 2.06 | - | - |
| Neutrophils (%) | 0.61 ± 0.07 | - | - |
| Lymphocytes (%) | 0.31 ± 0.07 | - | - |
| Monocytes (%) | 0.08 ± 0.02 | - | - |
- Citation: Minic Janicijevic S, Jovanovic IP, Gajovic NM, Jurisevic MM, Debnath M, Arsenijevic NN, Borovcanin MM. Galectin-3 mediated risk of inflammation in stable schizophrenia, with only possible secondary consequences for cognition. World J Psychiatry 2022; 12(9): 1183-1193
- URL: https://www.wjgnet.com/2220-3206/full/v12/i9/1183.htm
- DOI: https://dx.doi.org/10.5498/wjp.v12.i9.1183